Systemic sclerosis & Raynaud's
Detection of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease using home monitoring in the Netherlands (DecreaSSc): a prospective, observational study
Authors' conclusion
Home spirometry has the potential to detect a decline in pulmonary function in patients with systemic sclerosis-associated ILD earlier when used in addition to regular health care management.
Study context
- Population
- Adults with SSc (ACR-EULAR criteria), disease duration ≤5 years, HRCT-confirmed interstitial lung disease (ILD), ≤8 weeks immunosuppressive treatment at baseline; two tertiary centres, the Netherlands31 completed 12 months
- Participants
- 43 adults
- Exposure
- Weekly home spirometry vs hospital pulmonary function testing
- Outcome
- κ agreement between home and hospital measurements to detect a decline in force vital capacity (FVC) of 5% or more
- Follow-up
- 1 year
Methodological detailstwo tertiary referral centres, People with lived experience were involved at several stages of the study
- Two tertiary referral centres
- People with lived experience were involved at several stages of the study
Main finding
As reported in the abstract
κ agreement between home and hospital measurements to detect FVC decline ≥5%
κ agreement between hospital and home measurements
0.40
95% CI 0.01–0.79
Observational data: associations, not effects.
Further findings
| Outcome | Home spirometry |
|---|---|
| Detection of decline in FVC% predicted ≥5% (vs hospital pulmonary function test as gold standard) | |
| Sensitivity (95% CI 44-76) | 60% |
| Specificity (95% CI 75-98) | 87% |
Course of pulmonary function, hospital vs home assessment (regression interaction term)
- Interaction term, not significant
- −0.0003 (95% CI −0.0006 to 0.000008; p=0.057)
Longitudinal correlation between hospital and home measurements
- Longitudinal correlation
- 0.55 (95% CI 0.26-0.74; p=0.0070)
Cross-sectional correlation (intraclass coefficient) between both measurements
- Baseline
- 0.85 (95% CI 0.73-0.92; p<0.0001)
- 6 months (0.71-0.92; p<0.0001)
- 0.84
- 12 months (0.50-0.86; p<0.0001)
- 0.72
Original publication
Detection of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease using home monitoring in the Netherlands (DecreaSSc): a prospective, observational study. Lancet Rheumatol. Published 8 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →